Original Article

Vol. 32 No. 1 (2022): Psychiatry and Clinical Psychopharmacology

The Relationship of Plasma Transthyretin Level with Global or Regional Amyloid Beta Burden in Subjects with Amnestic Mild Cognitive Impairment: Cross-Sectional Amyloid PET Study

Main Article Content

Kangyoon Lee
Young-Min Lee
Je-Min Park
Byung-Dae Lee
Eunsoo Moon
Hee-Jeong Jeong
Hwagyu Suh
Hak-Jin Kim
Kyongjune Pak
Kyung-Un Choi

Abstract

Background: To investigate the relationships of plasma transthyretin levels with amyloid beta deposition and medial temporal atrophy in amnestic mild cognitive impairment.



Methods: This is a cross-sectional study of association of subjects with amnestic mild cognitive impairment. Plasma transthyretin levels, brain magnetic resonance imaging, and 18F-florbetaben positron emission tomography were simultaneously measured in subjects with amnestic mild cognitive impairment.



Results: Plasma transthyretin levels were positively associated with amyloid beta deposition in global (r=0.394, P=.009), frontal cortex (r=0.316, P=.039), parietal cortex (r=0.346, P=.023), temporal cortex (r=0.372, P=.014), occipital cortex (r=0.310, P=.043), right posterior cingulate (r=0.350, P=.021), left precuneus (r=0.314, P=.040), and right precuneus (r=0.398, P=.008). No association between plasma transthyretin level and medial temporal sub-regional atrophies was found.



Conclusions: Our findings of positive association of plasma transthyretin levels with global and regional amyloid beta burden suggest upregulation of transthyretin level as a reactive response to amyloid beta deposition during the early stages of the Alzheimer’s disease process.



Cite this article as: Lee K, Lee Y-M, Park J-M, et al. The relationship of plasma transthyretin level with global or regional amyloid beta burden in subjects with amnestic mild cognitive impairment: cross-sectional amyloid PET study. Psychiatr Clin Psychopharmacol. 2022;32(1):4-8.


Article Details